InsuLine Medical Ltd. is attracting a great deal of attention after the company reported it had signed a memorandum of understanding with Johnson and Johnson. Under the memorandum of understanding, InsuLine and Johnson and Johnson will cooperate immediately in obtaining regulatory approval for marketing InsuPad, which reduces injected insulin uptake speed in diabetics by near 50%. Johnson and Johnson will also manage registration procedures with the various authorities.

Once regulatory approval for marketing is obtained, the parties will negotiate a final binding distribution agreement for each territory, in which Johnson and Johnson will be the sole distributor. In addition to Russia, the agreement will also include Ukraine and other former Soviet Union countries Belarus, Armenia, Azerbaijan, Georgia, Kazakhstan, Kirgizstan, Moldova, Tajikistan, Turkmenistan, and Uzbekistan. The registration procedure is likely to take a year.